N’Djetchi, Martial Kassi
Camara, Oumou
Koffi, Mathurin
Camara, Mamadou
Kaba, Dramane
Kaboré, Jacques
Tall, Alkali
Rotureau, Brice
Glover, Lucy
Traoré, Mélika Barkissa
Koné, Minayegninrin
Coulibaly, Bamoro
Adingra, Guy Pacome
Soumah, Aissata
Gassama, Mohamed
Camara, Abdoulaye Dansy
Compaoré, Charlie Franck Alfred
Camara, Aïssata
Boiro, Salimatou
Anton, Elena Perez
Bessell, Paul
Van Reet, Nick
Bucheton, Bruno
Jamonneau, Vincent
Bart, Jean-Mathieu
Solano, Philippe
Biéler, Sylvain
Lejon, Veerle http://orcid.org/0000-0002-6795-0962
Funding for this research was provided by:
Swiss Agency for Development and Cooperation (81071426, 7F-08866.03.01)
Bill and Melinda Gates Foundation (INV-001785, OPP1033712, OPP1154033, INV-031353)
Article History
Received: 19 April 2024
Accepted: 25 June 2024
First Online: 8 July 2024
Declarations
:
: The protocol and informed consent forms of the study “Prospective evaluation of the SPEcificity of SERological tests for human African TRYPanosomiasis in Côte d’Ivoire and Guinea (SpeSerTryp), received approval from the Consultative Ethics Committee for Research in Partnership of the French National Institute for Research on Sustainable Development (IRD), from the National Ethics Committee on life sciences and Health (reference number 054-22/MSHPCMU/CNESVS-kp) in Côte d’Ivoire and from the National Ethics Committee on Health Research (reference number 069/CNERS/22) in Guinea. Before inclusion into the trial, potential study participants were provided with an explanation about the objectives, conduct, benefits and risks of the study in their language and their written informed consent was obtained. For minors, assent was obtained and parents or legal guardians provided a written informed consent. All study procedures were conducted according to the Declaration of Helsinki and in compliance with ICH Good Clinical Practice (GCP) E6 (R2). The study was registered in clinicaltrials.gov under identifier NCT05466630.
: Not applicable.
: The authors declare that they have no competing interests.